Showing 20 of 48 recruiting trials for “Tumor of hematopoietic and lymphoid tissues”
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
👨⚕️ Hannah Choe, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Jun 2026View details ↗
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
👨⚕️ James N Kochenderfer, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Apr 2026View details ↗
BY002 IIT Study in R/R Acute Leukemia
👨⚕️ Suning Chen, MD, PhD, The First Affiliated Hospital of Soochow University📍 1 site📅 Started Mar 2026View details ↗
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
👨⚕️ Swati Naik, MBBS, St. Jude Children's Research Hospital📍 1 site📅 Started Mar 2026View details ↗
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever
👨⚕️ Abby P Douglas, MBBS PhD FRACP, Peter MacCallum Cancer Centre; National Centre for Infections in Cancer📍 2 sites📅 Started Dec 2025View details ↗
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
👨⚕️ Roman Henkel, PhD, Director, Global Clinical Operations📍 2 sites📅 Started Sep 2025View details ↗
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
👨⚕️ Douglas Sborov, MD, MS, Huntsman Cancer Institute/ University of Utah📍 1 site📅 Started Sep 2025View details ↗
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
👨⚕️ Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company📍 6 sites📅 Started Aug 2025View details ↗
Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia
Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)
👨⚕️ Jonathan Webster, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins📍 1 site📅 Started Mar 2025View details ↗
Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
👨⚕️ Ginny Schulz, Ph.D., RN, CPNP-PC, Washington University School of Medicine📍 1 site📅 Started Nov 2024View details ↗
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
RecruitingNCT06537726 ↗
Breath Analysis for the Detection of Invasive Fungal Infections
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Page 1 of 3Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →